Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90

被引:0
作者
Ana Claudia Silva Braga
Bruno Moreira Carneiro
Mariana Nogueira Batista
Mônica Mayumi Akinaga
Paula Rahal
机构
[1] Letters and Exact Sciences,Institute of Biosciences
[2] UNESP,Institute of Exact and Natural Sciences
[3] Mato Grosso Federal University,undefined
来源
Cell Stress and Chaperones | 2017年 / 22卷
关键词
Hepatitis C; Hsp90; RNA interference; siRNA; HCV; Heat shock protein;
D O I
暂无
中图分类号
学科分类号
摘要
Hepatitis C (HCV) is a viral disease affecting millions of people worldwide, and persistent HCV infection can lead to progressive liver disease with the development of liver cirrhosis and hepatocellular carcinoma. During treatment for hepatitis C, the occurrence of viral resistance is common. To reduce the occurrence of resistance, new viral treatments should target both viral and cellular factors. Many interactions occur between viral and host proteins during the HCV replication cycle and might be used for the development of new therapies against hepatitis C. Heat shock protein 90 (Hsp90) plays a role in the folding of cellular and viral proteins and also interacts with HCV proteins. In the present study, we knocked down the expression of the Hsp90 gene and inhibited viral replication using siRNA molecules. Reducing the expression of Hsp90 successfully decreased HCV replication. All siRNA molecules specific to the viral genome showed the efficient inhibition of viral replication, particularly siRNA targeted to the 5′UTR region. The combination of siRNAs targeting the viral genome and Hsp90 mRNA also successfully reduced HCV replication and reduced the occurrence of viral resistance. Moreover, these results suggest that an approach based on the combination of cellular and viral siRNAs can be used as an effective alternative for hepatitis C viral suppression.
引用
收藏
页码:113 / 122
页数:9
相关论文
共 157 条
  • [11] Beck J(2016)Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data Scientific reports 6 20310-111
  • [12] Nassal M(2013)Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review Ann Intern Med 158 114-34
  • [13] Bian Z(2016)Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C Scientific reports 6 24867-761
  • [14] Brown KM(2003)Hepatitis C virus biology Cell Death Differ 10 S27-370
  • [15] Chu CY(2014)Global epidemiology and genotype distribution of the hepatitis C virus infection J Hepatol 61 S45-558
  • [16] Rana TM(2008)Impact of target mRNA structure on siRNA silencing efficiency: a large-scale study Biotechnol Bioeng 100 744-2128
  • [17] Bukowska-Osko I(2012)Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics BMC Cancer 12 38-354
  • [18] Caffrey DR(2014)Current and future therapies for hepatitis C virus infection: from viral proteins to host targets Arch Virol 159 831-765
  • [19] Carneiro B(2009)Guidelines for the nomenclature of the human heat shock proteins Cell Stress Chaperones 14 105-888
  • [20] Braga AC(2010)RNAi as a new therapeutic strategy against HCV Biotechnol Adv 28 27-5025